{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:04:20Z","timestamp":1786115060611,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004621","name":"Kerman University of Medical Sciences","doi-asserted-by":"publisher","award":["402000186"],"award-info":[{"award-number":["402000186"]}],"id":[{"id":"10.13039\/501100004621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-52109-2","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T08:44:32Z","timestamp":1779612272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic and potential prognostic associations of long noncoding RNAs LIFR-AS1 and SLCO4A1-AS1 in multiple myeloma"],"prefix":"10.1038","volume":"16","author":[{"given":"Mahmood","family":"Khosravi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behjat Kalantari","family":"Khandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Farsinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajar Mardani","family":"Valandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4487-8523","authenticated-orcid":false,"given":"Ali","family":"Afgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8626-4853","authenticated-orcid":false,"given":"Roohollah Mirzaee","family":"Khalilabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"issue":"7","key":"52109_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio, R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid neoplasms. Leukemia 36(7), 1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2 (2022).","journal-title":"Leukemia"},{"issue":"1","key":"52109_CR2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1158\/0008-5472.Can-07-3096","volume":"68","author":"W Matsui","year":"2008","unstructured":"Matsui, W. et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 68(1), 190\u20137. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-3096 (2008).","journal-title":"Cancer Res."},{"issue":"1","key":"52109_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74(1), 12\u201349. https:\/\/doi.org\/10.3322\/caac.21820 (2024).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"52109_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle, R. A. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 78(1), 21\u201333. https:\/\/doi.org\/10.4065\/78.1.21 (2003).","journal-title":"Mayo Clin. Proc."},{"issue":"10068","key":"52109_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s0140-6736(16)31594-x","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie, B. G. M. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial. Lancet 389(10068), 519\u201327. https:\/\/doi.org\/10.1016\/s0140-6736(16)31594-x (2017).","journal-title":"Lancet"},{"key":"52109_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11050334","author":"CC Leow","year":"2021","unstructured":"Leow, C. C. & Low, M. S. Y. Targeted therapies for multiple myeloma. J. Pers. Med. https:\/\/doi.org\/10.3390\/jpm11050334 (2021).","journal-title":"J. Pers. Med."},{"key":"52109_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/s24010037","author":"S Das","year":"2023","unstructured":"Das, S., Dey, M. K., Devireddy, R. & Gartia, M. R. Biomarkers in cancer detection, diagnosis, and prognosis. Sensors (Basel) https:\/\/doi.org\/10.3390\/s24010037 (2023).","journal-title":"Sensors (Basel)"},{"issue":"1","key":"52109_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13046-023-02741-x","volume":"42","author":"M Ahmad","year":"2023","unstructured":"Ahmad, M., Weiswald, L.-B., Poulain, L., Denoyelle, C. & Meryet-Figuiere, M. Involvement of lncRNAs in cancer cells migration, invasion and metastasis: Cytoskeleton and ECM crosstalk. J. Exp. Clin. Cancer Res. 42(1), 173. https:\/\/doi.org\/10.1186\/s13046-023-02741-x (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"52109_CR9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.omtn.2020.07.005","volume":"21","author":"D Fu","year":"2020","unstructured":"Fu, D. et al. Targeting long non-coding RNA to therapeutically regulate gene expression in cancer. Mol. Ther. Nucleic Acids 21, 712\u201324. https:\/\/doi.org\/10.1016\/j.omtn.2020.07.005 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"4","key":"52109_CR10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s13402-023-00806-9","volume":"46","author":"R Bhattacharjee","year":"2023","unstructured":"Bhattacharjee, R. et al. Crosstalk between long noncoding RNA and microRNA in cancer. Cell Oncol (Dordr) 46(4), 885\u2013908. https:\/\/doi.org\/10.1007\/s13402-023-00806-9 (2023).","journal-title":"Cell Oncol (Dordr)"},{"key":"52109_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ncrna5010013","author":"R Butova","year":"2019","unstructured":"Butova, R., Vychytilova-Faltejskova, P., Souckova, A., Sevcikova, S. & Hajek, R. Long non-coding RNAs in multiple myeloma. Noncoding RNA https:\/\/doi.org\/10.3390\/ncrna5010013 (2019).","journal-title":"Noncoding RNA"},{"issue":"23","key":"52109_CR12","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1080\/15384101.2021.1991122","volume":"20","author":"JQ Chen","year":"2021","unstructured":"Chen, J. Q. et al. M(6)A-mediated up-regulation of LncRNA LIFR-AS1 enhances the progression of pancreatic cancer via miRNA-150-5p\/ VEGFA\/Akt signaling. Cell Cycle 20(23), 2507\u201318. https:\/\/doi.org\/10.1080\/15384101.2021.1991122 (2021).","journal-title":"Cell Cycle"},{"issue":"9 Pt B","key":"52109_CR13","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1016\/j.bbadis.2018.05.020","volume":"1864","author":"K Liu","year":"2018","unstructured":"Liu, K. et al. Functional role of a long non-coding RNA LIFR-AS1\/miR-29a\/TNFAIP3 axis in colorectal cancer resistance to pohotodynamic therapy. Biochim. Biophys. Acta Mol. Basis Dis. 1864(9 Pt B), 2871\u201380. https:\/\/doi.org\/10.1016\/j.bbadis.2018.05.020 (2018).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"3","key":"52109_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1080\/01616412.2020.1836465","volume":"43","author":"H Ding","year":"2021","unstructured":"Ding, H., Cui, L. & Wang, C. Long noncoding RNA LIFR-AS1 suppresses proliferation, migration and invasion and promotes apoptosis through modulating miR-4262\/NF-\u03baB pathway in glioma. Neurol. Res. 43 (3), 210\u2013219. https:\/\/doi.org\/10.1080\/01616412.2020.1836465 (2021).","journal-title":"Neurol. Res."},{"key":"52109_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01228-5","volume":"20","author":"Q Wang","year":"2020","unstructured":"Wang, Q. et al. lncRNA LIFR-AS1 suppresses invasion and metastasis of non-small cell lung cancer via the miR-942-5p\/ZNF471 axis. Cancer Cell Int. 20, 180. https:\/\/doi.org\/10.1186\/s12935-020-01228-5 (2020).","journal-title":"Cancer Cell Int."},{"key":"52109_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/1698771","volume":"2021","author":"Q Li","year":"2021","unstructured":"Li, Q. et al. SLCO4A1-AS1 facilitates the malignant phenotype via miR-149-5p\/STAT3 axis in gastric cancer cells. J. Oncol. 2021, 1698771. https:\/\/doi.org\/10.1155\/2021\/1698771 (2021).","journal-title":"J. Oncol."},{"issue":"9","key":"52109_CR17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1080\/15384047.2020.1787757","volume":"21","author":"Q Li","year":"2020","unstructured":"Li, Q., Jiang, B., Qi, Y., Zhang, H. & Ma, H. Long non-coding RNA SLCO4A1-AS1 drives the progression of non-small-cell lung cancer by modulating miR-223-3p\/IKK\u03b1\/NF-\u03baB signaling. Cancer Biol. Ther. 21(9), 806\u201314. https:\/\/doi.org\/10.1080\/15384047.2020.1787757 (2020).","journal-title":"Cancer Biol. Ther."},{"key":"52109_CR18","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2020.11792","author":"J Zhao","year":"2021","unstructured":"Zhao, J. et al. LIFR\u2013AS1 inhibits gastric carcinoma cell proliferation, migration and invasion by sponging miR\u20134698. Mol. Med. Rep. 23(2), https:\/\/doi.org\/10.3892\/mmr.2020.11792 (2021).","journal-title":"Mol. Med. Rep."},{"key":"52109_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052805","author":"B Smolarz","year":"2022","unstructured":"Smolarz, B., Durczy\u0144ski, A., Romanowicz, H., Szy\u0142\u0142o, K. & Hogendorf, P. miRNAs in cancer (review of literature). Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms23052805 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"52109_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/15330338231202391","volume":"22","author":"A Tavakoli Pirzaman","year":"2023","unstructured":"Tavakoli Pirzaman, A. et al. miRNAs and multiple myeloma: Focus on the pathogenesis, prognosis, and drug resistance. Technol. Cancer Res. Treat. 22, 15330338231202391. https:\/\/doi.org\/10.1177\/15330338231202391 (2023).","journal-title":"Technol. Cancer Res. Treat."},{"key":"52109_CR21","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20180551","author":"F Xu","year":"2019","unstructured":"Xu, F., Li, H. & Hu, C. LIFR-AS1 modulates Sufu to inhibit cell proliferation and migration by miR-197-3p in breast cancer. Biosci. Rep. https:\/\/doi.org\/10.1042\/bsr20180551 (2019).","journal-title":"Biosci. Rep."},{"issue":"8","key":"52109_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24570","volume":"36","author":"F Liu","year":"2022","unstructured":"Liu, F., Cao, L., Zhang, Y., Xia, X. & Ji, Y. LncRNA LIFR-AS1 overexpression suppressed the progression of serous ovarian carcinoma. J. Clin. Lab. Anal. 36(8), e25470. https:\/\/doi.org\/10.1002\/jcla.24570 (2022).","journal-title":"J. Clin. Lab. Anal."},{"key":"52109_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1590815","volume":"2022","author":"Z Bai","year":"2022","unstructured":"Bai, Z., Wang, X. & Zhang, Z. Long noncoding RNA LIFR-AS1: A new player in human cancers. BioMed Res. Int. 2022, 1590815. https:\/\/doi.org\/10.1155\/2022\/1590815 (2022).","journal-title":"BioMed Res. Int."},{"issue":"2","key":"52109_CR24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.canlet.2009.08.013","volume":"289","author":"Y Okamura","year":"2010","unstructured":"Okamura, Y. et al. Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array. Cancer Lett. 289(2), 170\u20137. https:\/\/doi.org\/10.1016\/j.canlet.2009.08.013 (2010).","journal-title":"Cancer Lett."},{"key":"52109_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6020059","author":"P Roy","year":"2018","unstructured":"Roy, P., Sarkar, U. A. & Basak, S. The NF-\u03baB activating pathways in multiple myeloma. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines6020059 (2018).","journal-title":"Biomedicines"},{"issue":"13","key":"52109_CR26","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.7150\/ijbs.38041","volume":"15","author":"R Tang","year":"2019","unstructured":"Tang, R. et al. LncRNA SLCO4A1-AS1 predicts poor prognosis and promotes proliferation and metastasis via the EGFR\/MAPK pathway in colorectal cancer. Int. J. Biol. Sci. 15(13), 2885\u201396. https:\/\/doi.org\/10.7150\/ijbs.38041 (2019).","journal-title":"Int. J. Biol. Sci."},{"issue":"5","key":"52109_CR27","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/ijlh.13501","volume":"43","author":"J Mao","year":"2021","unstructured":"Mao, J., Gao, W., Xue, L., Wang, J. & Zhao, L. The lncRNA SLCO4A1-AS1\/miR-876-3p\/RBBP6 axis regulates cell proliferation and apoptosis in acute lymphocytic leukemia via the JNK signaling pathway. Int. J. Lab. Hematol. 43 (5), 1050\u20131061. https:\/\/doi.org\/10.1111\/ijlh.13501 (2021).","journal-title":"Int. J. Lab. Hematol."},{"issue":"1","key":"52109_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0896-y","volume":"37","author":"J Yu","year":"2018","unstructured":"Yu, J. et al. LncRNA SLCO4A1-AS1 facilitates growth and metastasis of colorectal cancer through \u03b2-catenin-dependent Wnt pathway. J. Exp. Clin. Cancer Res. 37(1), 222. https:\/\/doi.org\/10.1186\/s13046-018-0896-y (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"52109_CR29","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/exd.14577","volume":"31","author":"K Wang","year":"2022","unstructured":"Wang, K. et al. SLCO4A1-AS1 triggers the malignant behaviours of melanoma cells via sponging miR-1306-5p to enhance PCGF2. Exp. Dermatol. 31(8), 1220\u201333. https:\/\/doi.org\/10.1111\/exd.14577 (2022).","journal-title":"Exp. Dermatol."},{"key":"52109_CR30","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.2147\/ott.S191740","volume":"12","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. lncRNA SLCO4A1-AS1 promotes growth and invasion of bladder cancer through sponging miR-335-5p to upregulate OCT4. Onco. Targets Ther. 12, 1351\u20138. https:\/\/doi.org\/10.2147\/ott.S191740 (2019).","journal-title":"Onco. Targets Ther."},{"key":"52109_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155358","volume":"138","author":"J Gu","year":"2021","unstructured":"Gu, J. et al. Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels. Cytokine 138, 155358. https:\/\/doi.org\/10.1016\/j.cyto.2020.155358 (2021).","journal-title":"Cytokine"},{"key":"52109_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155210","volume":"134","author":"A Ben Hmid","year":"2020","unstructured":"Ben Hmid, A. et al. RORC overexpression as a sign of Th17 lymphocytes accumulation in multiple myeloma bone marrow. Cytokine 134, 155210. https:\/\/doi.org\/10.1016\/j.cyto.2020.155210 (2020).","journal-title":"Cytokine"},{"issue":"3","key":"52109_CR33","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/cam4.5135","volume":"12","author":"J Qin","year":"2023","unstructured":"Qin, J. et al. Aberrantly expressed long noncoding RNAs as potential prognostic biomarkers in newly diagnosed multiple myeloma: A systemic review and meta-analysis. Cancer Med. 12(3), 2199\u2013218. https:\/\/doi.org\/10.1002\/cam4.5135 (2023).","journal-title":"Cancer Med."},{"issue":"10","key":"52109_CR34","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.26355\/eurrev_202005_21321","volume":"24","author":"HF Wang","year":"2020","unstructured":"Wang, H. F., Lv, J. Q., Li, H. H., Wang, W. & Lin, F. Q. High long non-coding LIFR-AS1 expression correlates with poor survival in gastric carcinoma. Eur. Rev. Med. Pharmacol. Sci. 24(10), 5378\u201384. https:\/\/doi.org\/10.26355\/eurrev_202005_21321 (2020).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"1","key":"52109_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-82109-z","volume":"15","author":"Y Wu","year":"2025","unstructured":"Wu, Y. et al. Super-enhancer-driven SLCO4A1-AS1 is a new biomarker and a promising therapeutic target in glioblastoma. Sci. Rep. 15(1), 954. https:\/\/doi.org\/10.1038\/s41598-024-82109-z (2025).","journal-title":"Sci. Rep."},{"key":"52109_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.973836","volume":"12","author":"AG Solimando","year":"2022","unstructured":"Solimando, A. G. et al. Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche. Front. Oncol. 12, 973836. https:\/\/doi.org\/10.3389\/fonc.2022.973836 (2022).","journal-title":"Front. Oncol."},{"issue":"9","key":"52109_CR37","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar, S. V. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 99 (9), 1802\u20131824. https:\/\/doi.org\/10.1002\/ajh.27422 (2024).","journal-title":"Am. J. Hematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52109-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52109-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52109-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T23:44:35Z","timestamp":1785973475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52109-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["52109"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-52109-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,24]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol received approval from the Research Ethics Committee at the Kerman University of Medical Sciences (ID number: IR.KMU.REC.1402.304). and all patients and controls signed an informed consent document in accordance with the statement of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study in compliance with the Declaration of Helsinki. In order to publish this manuscript, written informed consent has been obtained from all study subjects.","order":3,"name":"Ethics","label":"<b>Patient consent <\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All laboratory procedures involving human blood samples were conducted in a BSL-2 (Biosafety Level 2) facility, adhering to standard biosafety protocols to ensure the safety of personnel and the environment. The research utilized only human-derived RNA and did not involve the manipulation of pathogenic microorganisms or toxins. Therefore, this study did not raise significant biosecurity concerns as defined by international dual-use research of concern guidelines.","order":4,"name":"Ethics","label":"Biosafety and Biosecurity","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24288"}}